Pfizer remains dedicated to a patient-centric approach for those living with cardiovascular and metabolic diseases.
Lead the conversation

Committed to Cutting-Edge Research in Cardiovascular and Metabolic Diseases

Pfizer remains dedicated to a patient-centric approach for those living with cardiovascular and metabolic diseases.

For decades, Pfizer has been at the forefront of novel treatments for people living with cardiovascular and metabolic diseases. Our commitment continues to grow as our knowledge of underlying metabolic drivers leads us to new approaches to addressing unmet medical needs. In addition to partnerships, such as our recentlicensing agreement with Akcea Therapeutics, our scientists are pursuing cutting-edge research to both advance our understanding and investigate potential therapies for conditions like nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes and cachexia.

The patient remains firmly at the center of these efforts, inspiring our science as well as our educational outreach, including a“Dear Scientist” patient story about the challenges of NASH and adisease primer on cachexia.

Unleash the power of our people
Deliver first-in-class science
Transform our go-to-market model
Win the digital race in pharma
Lead the conversation